News - Bayer, Stivarga


Current filters:


Popular Filters

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG


There was a hint of positive news for German drug major Bayer, when the German Institute for Quality…

BayerGermanyNorthern EuropeOncologyPharmaceuticalPricingRegulationStivarga

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market


From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Bayer files for EU approval of regorafenib for GIST


German pharma major Bayer (BAYN: DE) said this morning (September 5) that it has submitted an application…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationStivarga

Bayer and Onyx' Stivarga cleared in Europe


In a second piece of good news within a couple of days for German drug major Bayer (BAYN: DE), the European…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

Bayer gets Japanese OK for GI stromal tumors drug


German drug major Bayer (BAYN: DE) has received approval from the Ministry of Health, Labor and Welfare…


US and European Rxing decisions on metastatic colorectal cancer


The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Bayer initiates Ph III Stivarga study in liver cancer; Sanofi enrolls sarilumab patients


German drug major Bayer (BAYN: DE) says that patient enrollment is underway for RESORCE (Regorafenib…


FDA expands use of Bayer and Onyx' Stivarga for advanced GIST


The US Food and Drug Administration yesterday expanded the approved use of German drug major Bayer's…

BayerNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

Bayer's regorafenib overcomes resistance in patients with rare sarcoma


A new targeted drug - German drug major Bayer's (BAYN: DE) regorafenib (trade name Stivarga) - demonstrated…


Bayer initiates Ph III trail of Xarelto in cardiac event prevention; R&D day presentation


German drug major Bayer (BAYN: DE) has initiated the Phase III COMPASS study of its oral anticoagulant…


News briefs: Bayer's Stivarga and AstraZeneca's Faslodex


German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday…

AstraZenecaBayerFaslodexNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationResearchStivarga

Bayer's Stivarga races to FDA approval on the heels of Zaltrap


The earlier than expected US Food and Drug Administration approval of German drug major Bayer's (BAYN:…

BayerBiotechnologyMarkets & MarketingNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationSanofiStivargaZaltrap

Early FDA approval for Bayer's Stivarga in advanced colorectal cancer


Bayer said Stivarga will be ready for distribution as soon as today (September 28 and set a wholesale…

BayerNorth AmericaOncologyPharmaceuticalregorafenibRegulationStivarga

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top